Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great find.
May I ask how you find these, are you just looking at the daily filings?
I started using RSS feeds on my favorite tickers thru the sec website. Helps when the company files 8k without a formal press release.
CSPI...Now @ $12...Stay tuned for next week's webinar...
(I added back a bit today going into the webinar & earnings)
ARIA and Rockwell Automation Discuss the Unique Requirements to Protect Industrial Applications in Their Latest Webinar
Webinar: CybeRx - How to Automatically Protect Rockwell OT Customers from Today's Cyber-attacks
LOWELL, MA / ACCESSWIRE / April 25, 2024 / ARIA Cybersecurity Solutions, a CSPi business (NASDAQ:CSPI), has warned of the rapidly escalating cybersecurity risks facing companies with operational technology (OT) in the manufacturing sector. In a new webinar, "CybeRx - How to Automatically Protect Rockwell OT Customers from Today's Cyber-Attacks" we will discuss why the Perdue model, passive defenses and AV/NGAV are not stopping the most dangerous attacks.
In this webinar you will hear from Rockwell about the unique set of requirements that are needed to protect your production application's attack surface and how Aria's AZT Protect has helped meet this need. We will delve into the composition of supply chain attacks and finally hear about a case study in how one of the world's largest pharma manufactures used ARIA AZT PROTECT in combination with Rockwell's industrial automation suite to protect their environment and meet their challenging OT requirements.
Gary Southwell, General Manager of ARIA Cybersecurity, is joined by Thomas House, Life Sciences Cyber and Digital Consultant, Rockwell Automation.
Webinar scheduled for Thursday, May 9, 2024
11:00 AM EDT
To access the full webinar, please visit: https://hubs.ly/Q02t-sv20
https://finance.yahoo.com/news/aria-rockwell-automation-discuss-unique-120000711.html
DRTK thanks for the alert
Followed this for years, and figured it would find its way to sub-penny eventually. This was not the zombie corpse I thought would ever rise again.
Grabbed a few DTRK($.40); P/E is 1
This morning, the company reported diluted 2023 EPS of $.38. And then there was this from the PR; they reported
"Closing the company’s largest sales contract in a decade that provides seven-figure
recurring revenue for the company for the next several years and likely to expand into
additional future revenues."
https://www.otcmarkets.com/otcapi/company/dns/news/document/74354/content
GERN - Seeking Alpha article
Geron: FDA PDUFA Review With Continued Imetelstat Advancement
May 01, 2024 4:23 PM ETGeron Corporation (GERN) StockGERNW6 Comments
Terry Chrisomalis profile picture
Terry Chrisomalis
Investing Group Leader
Summary
Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome.
The FDA Oncologic Drugs Advisory Committee already voted in favor of imetelstat 12 to 2 for patients with low-risk myelodysplastic syndrome.
The European Commission has already accepted the MAA for review of imetelstat for low-risk myelodysplastic syndrome; European approval is possible in 2025.
Imetelstat is also being evaluated in the ongoing phase 3 IMpactMF study for the treatment of patients of relapsed/refractory MF; Interim analysis expected in the 1st half of 2025 and final data expected in the 1st half of 2026.
Tablet, reading and woman scientist in laboratory working on medical research, project or experiment. Science, career and female researcher with digital technology for pharmaceutical innovation.
Jacob Wackerhausen
Geron Corporation (NASDAQ:GERN) is gearing up for a major milestone as a biotech company. It has a PDUFA date set for June 16th of 2024, which is the date by which the FDA will decide whether imetelstat should be approved for the treatment of patients with low-risk myelodysplastic syndrome [LR-MDS]. These are patients who have failed to respond, lost response to or ineligible for Erythropoiesis-stimulating agents [ESAs]. An FDA advisory panel already voted in favor of imetelstat for this LR-MDS patient population, recommending that the risk-benefit profile is ideal for regulatory approval of it.
The FDA still has to approve it based on this recommendation. However, with such a recommendation, I don't see how the FDA could reject approval. This regulatory approval is only going to be based on its ability to market this drug in the United States only.
It is already in the process of having imetelstat reviewed for the same patient population for Europe. That is, the European Commission [EC] is already in the process of reviewing it for possible approval for all the European territories as well. Should the review go well, then it is expected that this drug could possibly be approved for these territories in 2025. Lastly, the goal is to advance imetelstat for multiple indications. As such, it is also running another phase 3 study as part of its pipeline known as IMpactMF, which is using imetelstat for the treatment of patients with relapsed/refractory Myelofibrosis [MF] or r/r MF. An interim analysis from this trial is expected in the 1st half of 2025 and from there, a final analysis from this late-stage study is expected in the first half of 2026.
FDA Review Date Catalyst Rapidly Approaching For Imetelstat
The main program in Geron's pipeline would be the use of imetelstat for the treatment of patients with low-risk myelodysplastic syndrome [LR-MDS]. These are patients who do not even respond to standard of care [SOC] Erythropoiesis-stimulating agents [ESAs]. The potential here is massive because it has already gone on to accomplish several items to potentially obtain FDA approval of imetelstat for the treatment of this patient population. Matter of fact, everything seems to be lining up perfectly thus far. The only hurdle left now would be the actual FDA review date that has been set up. This is a PDUFA date of June 16th of 2024, where the agency will decide whether imetelstat should be approved for the treatment of these patients with LR-MDS. Myelodysplastic Syndrome [MDS] is a type of blood disorder characterized as the spongy material inside the bones not working properly. In turn, it cannot produce red blood cells [RBCs] in an adequate fashion for these patients. Some symptoms that these patients experience are as follows:
Shortness of breath
Fatigue
Pale skin color due to anemia
Unusual types of bruising occurring.
The global Myelodysplastic Syndrome market is expected to reach $6.63 billion by 2030. However, in the case of Geron, it is specifically going after low-risk Myelodysplastic Syndrome patients. This is a huge population to go after still, even if it were only to target this subpopulation.
What makes me say that? Well, it is said that approximately 68% of patients remain in the low-risk category. Plus, there is another highly important item to note, which is that the patients being targeted are an unmet need. These are low-risk MDS patients who have failed to respond, stop responding to, or ineligible to receive SOC Erythropoiesis-stimulating agents [ESAs]. What are these ESAs, and how do they help these patients? In essence, what they do is stimulate the bone marrow to produce more RBCs than a patient needs. In addition, it is also used to greatly reduce the number of blood transfusions being done.
The real question is, why should investors look into this upcoming PDUFA date of imetelstat for the treatment of these LR-MDS patients? As with all regulatory drug approvals, nothing is guaranteed. However, in this case, I believe that there is a good chance that it be approved to treat this specific patient population. The basis of this statement is because of the highly positive vote that was obtained from the FDA advisory panel. That is, the FDA Oncologic Drugs Advisory Committee voted 12 to 2 in favor of recommending approval of imetelstat. This is highly positive, and I believe there is a good chance that it will be approved. However, it is ultimately up to the FDA and there is always a chance that it may end up rejecting U.S. marketing approval. It's important to keep in mind that the FDA uses these panels as recommendations, but ultimately doesn't have to follow them.
Besides the positive vote, I believe there is another excellent reason on why FDA approval is almost guaranteed. It is because of the primary endpoint being met in the phase 3 IMerge study. This study recruited such low-risk MDS patients and was testing the use of imetelstat compared to placebo because of transfusion independence over a consecutive 8-week period for 12 months. Most MDS patients have a need for transfusions to be able to stimulate their blood cells; thus, the primary endpoint was to achieve red blood cell transfusion independence [RBC-TI] over this period. It was shown that RBC-TI was superior in the imetelstat treatment group compared to the placebo treated group. As such, treatment with the drug was statistically significant compared to placebo, with a p-value of p<0.001.
If it were only the FDA PDUFA date approaching as a milestone in terms of regulatory approval, that would be one thing, but there might be another territory that it could receive approval of imetelstat for. This would be regarding an already submitted Marketing Authorization Application [MAA] of this drug for the treatment of this patient population to the European Commission [EC]. If the review for this territory goes well, then Geron can possibly also receive marketing approval of imetelstat for LR-MDS patients in the European territories in 2025 as well.
Possible Expansion Opportunity Of Imetelstat Can Lead To Another Catalyst
The thing is that while the PDUFA date is a near-term catalyst that Geron has, that doesn't mean that it is not working on expanding the use of imetelstat towards the treatment of other hematological malignancy [blood cancer] patient populations. The reason why this is possible is because of telomerase inhibition, whereby telomerase is no longer in place. Without telomerase being in place, this leads to cells becoming shorter upon division and eventually dying off [apoptosis].
To see if Geron can advance the use of imetelstat for another blood disorder, it has initiated a phase 3 study known as IMpactMF. This particular late-stage study is using this drug to treat patients with relapsed/refractory myelofibrosis [MF]. That is, to recruit intermediate-2 to high-risk MF patients who relapse after Janus associated kinase [JAK] inhibitor treatment. Myelofibrosis [MF] is characterized as a rare bone marrow cancer where scarring occurs, thus leading to a lower than expected production of red blood cells [RBCs].
This low amount of blood cells leads to anemia [low blood cell count], which leads to weakness or fatigue. The global Myelofibrosis market size is projected to reach $2.89 billion by 2031. However, Geron believes that between the United States and Europe for the targeting of relapsed/refractory MF patients, it could target a >$3.5 billion market opportunity.
How is it even possible for imetelstat to help these r/r MF patients? That's because of how dire this patient population is. Especially, when you find out that a large majority of them fail when taking JAK inhibitors. It is noted that there is a discontinuation rate of 75% after 5 years with this treatment option. Thus, a drug like imetelstat could be given instead to patients that might improve their response. Having said that, this IMpactMF phase 3 study, is a first of its kind trial deploying overall survival [OS] as the primary endpoint for this specific study.
The reason why I brought up this program is that in the early part of next year, there is a major milestone expected for it. It is expected that an interim analysis from this phase 3 IMpactMF study will be released in the 1st half of 2025. From there, a full final analysis from this late-stage registrational trial is expected to be released in the 1st half of 2026.
Financials
According to the 10-K SEC Filing, Geron Corporation had cash, cash equivalents and marketable securities of $378.1 million as of December 31, 2023. The reason for the cash on hand is because of several financial transactions it enacted in 2023. It received about $213.3 million from an underwritten public offering of common stock and pre-funded warrants in January 2023.
In addition, it received $105.9 million from the exercise of outstanding warrants and $29.7 million in net proceeds drawn down from a Loan Agreement with Hercules and SVB. It believed that this would be enough cash to fund its operations into Q3 of 2025. However, it also has to account for the funds it will need to prepare for possible commercialization of imetelstat for LR-MDS. As such, it enacted a huge cash raise with the pricing of an underwritten offering. With this offering, it raised approximately $150 million in gross proceeds.
With the cash on hand, plus the gross proceeds raised from this recent offering, this should extend Geron Corporation's cash runway into the early part of 2026. Its cash burn is about $394.6 million per year.
Risks To Business
There are several risks that investors should be aware of before investing in Geron. The first risk to consider would be regarding the upcoming PDUFA date of June 16th of 2024, where the FDA will decide if imetelstat should be approved for the treatment of patients with low-risk myelodysplastic syndrome [LR-MDS]. Even though the advisory FDA panel voted in favor of recommending imetelstat for the treatment of this patient population, there is no assurance that U.S. marketing approval will be achieved. As I stated above, the FDA only takes the recommendation of the advisor panel, but it doesn't have to abide by it.
A second risk to consider would be regarding the ongoing review by the European Commission [EC] of imetelstat for the treatment of patients with low-risk myelodysplastic syndrome. Even though the regulatory application was accepted for review, there is no guarantee that the drug will be approved for the treatment of this patient population in the European territories.
The third and final risk to consider would be regarding the possible expansion opportunity of imetelstat I described above. This would be regarding the ongoing phase 3 IMpactMF study, which is using this drug for the treatment of patients with relapsed/refractory MF. An interim analysis from this late-stage trial is expected to happen in the early part of 2025 and there is no assurance that positive results will be achieved for it. Nor, that there will be a positive outcome when the final analysis is revealed in 2026.
Conclusion
Geron Corporation is gearing up to have a huge inflection point for investors to keep an eye on. This would be regarding the PDUFA review date of June 16th of 2024 of imetelstat for the treatment of patients with transfusion-dependent [TD] anemia in adult patients with LR-MDS who have not responded to or lost response to or are ineligible for erythropoiesis stimulating agents [ESAs]. This possible regulatory approval for this drug is only the beginning because there is an ongoing review by the European Commission for the European territories.
I believe that the last point to make is that telomerase expression is observed in about 90% of biopsies taking in various types of cancer. As such, it has already advanced its pipeline towards the use of imetelstat for the targeting of front-line MF patients [IMproveMF] and for the targeting of relapsed/refractory acute myeloid leukemia and high-risk MDS patients [IMpress]. There is no assurance that the drug will work out for either of these other hematological malignancies, but they do provide additional shots on goal for the pipeline.
Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
This article was written by
Terry Chrisomalis profile picture
Terry Chrisomalis
12.38K Followers
Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.
He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Learn more.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Comments (6)
Get Access to exclusive premium content, real-time chat and much more by Terry Chrisomalis with:
Terry Chrisomalis profile picture
Biotech Analysis Central
?????
?????
Recommended For You
Comments
Breaking - Peloton Interactive gains after announcing CEO resignation, more jobs cuts
Great summary. SMCI will earn about 8 this quarter, about 40 in the fiscal year starting July 1, 2024, and grow many quarters to come because of her competitive advantage.
SMCI forecasting 30%+ revenue growth in current quarter
versus quarter just reported...
SMCI forecasts 5.1 billion to 5.5 billion
for current quarter versus the 3.85 billion
for quarter just reported...
CC transcript link...
https://finance.yahoo.com/news/super-micro-computer-inc-nasdaq-144129328.html
DLC server rack items caused a
surge in inventory at end of quarter
just reported to meet the demand
coming in the current quarter...
CC actually helped explain things...
It doesn't forecast the distant future,
but it hints the sell off was overdone...
So we watch...LJ
Wildcard seems holding anything with good earnings
in this market right now...
Hopefully, the market got the J.P.
flop out of its system...
Timing is bad for oil/gas companies
reporting now with oil price falling and
little relief from spot natural gas prices...
And of course, this is a market that can
forget that these are high oil prices...
So we watch...LJ
JAZZ
Reported after the bell. The quarter was clearly a miss to analyst expectations (Basically missed by $1.50), but guidance remains the same. hence my opinion remains unchanged.
Why do I feel confident they will hit guidance for the fy if not exceed it? It really does beg the question are you just ignoring the facts that you might be wrong here. Let me explain why I feel I'm not wrong.
Well Q1 $2.68 had many moving parts. For starter q1 is seasonally weak, many of there drugs get stocked up late in the FY q3 and q4, and q1, is a working off inventory type of quarter hence that was a significant factor to top line growth of numerous drugs which will increase significantly in q2 and continued ramp throughout the year. So q1 will always be much weaker than the other quarters, so you can never annualize q1 because of it.
Revs were also affected by a huge drop in Xyrem revs, as people have switched to Xrwav, shown by a decent (As they said one time significant jump in a sequential jump in Xrwav patients. The good news is there people will be paying customers (Most likely) The bad news is to get them off Xyrem to Xrwav, is basically a 1-2 month thing, where the company basically provides free samples is my understanding from the cc. Now They generally get the insurance to cover these patients going foward (But it takes 1-2 months to make the switch/transition) so these people will be paying customers by there insurance come q2 and beyond (At least for the most part), but as a result we got a much larger drop in Xyrem revs because of this, and the Xrwav Revs Will grow significantly in q2 (But the increase in patients didn't really help q1 revs very much) and beyond sequentially, but because of the process my understanding is this was another significant headwind in q1, but with benefit in q2 and beyond as obviously JAZZ is moving the revs to Xyrev, and the royalities from the high sodium oxbate, is how they will get there revs going foward as Xyrem because much, much less important.
Furthermore SGA had some higher legal costs, and a higher bad debt expense, that they gave the idea that this stuff probably won't continue at these levels in future quarters.
Furthermore the tax rate was significantly higher for q1 than where it was and is forecasted to be. Hence that almost hit earnings for another .50 right there alone. But they indicate the tax rate remain unchanged for the year, with a timing issue hence that will help EPS in future quarters.
Furthermore I'm very excited about the pipeline. With Zantidamab more near term in fact revs might be coming in as early 2025 if we get approval if not sooner. Longer-term this drug is projected to possibly have a 2 billion+ peak potential. of course still unknown if it can get there or even approved for that matter, and with all drugs they are like prospects in baseball, but it sure does sound exciting, granted I'm no medical expert.
Furthermore on the slides they talked about fy 25. They talked about getting adjusted operating margins up 5% from fy 21 levels, which were around 43%. The are talking about being at 43% for the rest of the year, so 5% more, if they even come close, and forget the 500 million in business development revs, even if they do 4.5 billion in fy 25. Things get very exciting if they increase operating margins anywhere near that.
I still see alot of waaaaaaaaaaays to win with JAZZ here. of course i won't be surprised if it is down tomorrow possibly making a new 52 week lows, but I still think they could do close to $20 this year (Market won't probably give them the benefit of the doubt), Considering they have an impressive pipeline, and possible increase in adjusted operating margins in fy 25, combined with increased revenue growth from it's existing drugs, and possibly the introduction of a possible huge blockbuster on zantidamab, and the drop in Xyrem will start to have less effect on results to overcome as the amount of revs is getting much smaller as a part of total revs in my opinion, at a absurdly cheap valuation. Anyways time will tell, but wanted to give an update on what I thought about JAZZ, obviously the quarter on the face number was very disappointing, but there are reasonable reason for what happened here, and why they should hit guidance in FY 24, and possibly even better news in FY 25. Time will tell. All is just my opinion, and I could always be wrong though.
CLMB...Earnings report came in a bit soft (although not terrible). Taken from the management commentary..."During the quarter we experienced softer volumes across select key vendors, primarily related to the timing of their respective sales cycles. This includes a key vendor from our acquisition of DataSolutions in October 2023. Although this adversely affected our bottom line in Q1, we expect to return to growth with these vendors in the back half of the year."
The cc is early tomorrow. Should be interesting.
Climb Global Solutions Reports First Quarter 2024 Results
Q1 2024 Net Sales Up 9% YoY to $92.4 Million, with Adjusted Gross Billings Up 16% to $355.3 Million
EATONTOWN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb”, the “Company”, “we”, or “our”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, is reporting results for the first quarter ended March 31, 2024.
First Quarter 2024 Summary vs. Same Year-Ago Quarter
Net sales increased 9% to $92.4 million.
Adjusted gross billings (a non-GAAP financial measure defined below) increased 16% to $355.3 million.
Net income was $2.7 million or $0.60 per diluted share compared to $3.3 million or $0.74 per diluted share.
Adjusted EBITDA (a non-GAAP financial measure defined below) was $5.5 million compared to $5.7 million.
https://finance.yahoo.com/news/climb-global-solutions-reports-first-200500876.html
SBOW...Should be up tomorrow. FTK & AESI are two big o&g holdings for me and they both report next week. Think I'll be OK holding those 2 into earnings also. We'll see what happens.
SSKMP Managed Index (As Of 5/1/24)
Daily Performance
+0.08%
YTD Performance
+0.99%
Overall Performance
+476.50% (Including Options Trading +340.48%)
SBOW looks like a strong quarter .... adj EPS of $2.09 beat analyst estimates for $1.58. Free cash flow was strong allowing a pay down of debt. The derivative loss was expected since crude oil prices rose from $72 at year end to $83 on 3/31/24, hence the mark to market writedown of their future period hedging position.
The big wildcard remains oil prices which have been falling recently -
https://oilprice.com/Latest-Energy-News/World-News/Oil-Prices-Plummet-3-on-US-Inventory-Build-Inflation.html
AYSI/KIK: Nope
My last interaction with their phone "support" didn't leave me with any confidence in their competence nor any desire to waste more time.
I infer from your post that your email went nowhere either.
SBOW...Earnings are out. I'm not an o&g expert, but at first glance, the report looks good...
(adj EPS $2.09)
SilverBow Resources Announces First Quarter 2024 Financial and Operating Results
Results top consensus expectations driven by higher production and lower capital expenditures generating record quarterly EBITDA and strong quarterly free cash flow
Total debt reduced by $178 million since closing its South Texas acquisition in late 20231; First quarter 2024 leverage ratio of 1.35x2 lower than pre-acquisition announcement
Year-to-date outperformance leads to increase in full-year production expectations and free cash flow outlook
https://ih.advfn.com/stock-market/NYSE/silverbow-resources-SBOW/stock-news/93762382/silverbow-resources-announces-first-quarter-2024-f
SSKMP Trades
Buy 125 Shares of GPN
Note that this is a fictional portfolio and is not a recommendation to buy or sell securities
Market Commentary -
briefing -
Going into Fed Chair Powell's press conference, the market was nervous about the possibility of Fed Chair Powell sounding more hawkish than he did at the March FOMC press conference. The key thought around that nervous feeling was that Fed Chair Powell would connote the notion that it is increasingly possible that the Fed will elect to raise rates further.
He said (and we quote): "I think it's unlikely that the next policy rate move will be a hike. I would say it's unlikely."
The fact that the stock market and the Treasury market rallied initially on that acknowledgment should come as no surprise. It was (relief) music to their ears.
From our vantage point, Fed Chair Powell worked hard to shoot down the prospect of another rate hike, sticking instead to the view that the Fed will stick with its current policy stance as long as it is appropriate and that a path to cutting rates would follow inflation moving sustainably towards the Fed's 2% target or an unexpected weakening in the labor market.
Fed Chair Powell clarified that a couple of tenths higher in the unemployment rate itself would probably not qualify as a meaningful weakening in the labor market.
By and large, the Fed seems stuck with its current policy stance, which is a byproduct of economic data for a data-dependent Fed that has occasionally run hot, has oftentimes run warm, and has rarely turned cold. Accordingly, it keeps the Fed guessing like the rest of us if the policy stance is truly appropriate or will be revealed in hindsight to be too restrictive or not restrictive enough.
The Fed Chair is convinced that the evidence shows pretty clearly that policy is restrictive and is weighing on demand; however, gaining greater confidence in inflation moving sustainably toward 2%, he said, will take longer than previously expected.
So, the market is stuck with the uncertainty of how long the current policy rate will be in effect, which means it will be stuck with higher rates for longer as an uncertain Fed tries to understand if it has done enough, or needs to do more, to get inflation back to 2%.
The Russell 2000 is up 1.5%; the Dow Jones Industrial Average is up 0.7%; the Nasdaq Composite is up 0.5%; and the S&P 500 is up 0.2%.
Hey manjb, have you called the AYSI people again since this post? Have you heard when/if the $$ will hit our accounts? TIA
Hope you got some already? I bought back 90% short term SMCI shares at 742, 730, 720 and 710. Additional 10% at 700 has not been filled! This is the company which is so well managed that it has not had one loss years since its IPO!
GPN
Added more today at $109.45. Obviously my entry point for starters wasn't great to say the least. But as I said I was going to do add more on weakness. Down over $5 from my initial Purchase Price qualifies as weakness. So I added more. All is just my opinion, and I could always be wrong though.
SBOW...Nice comparison.
SBOW - here's the stock price history compared to crude oil .... they do a lot of hedging so may fetch above or below market prices in any given quarter -
Date SBOW Oil
20230103 24.99 76.93
20230104 25.84 72.84
20230105 25.92 73.67
20230106 26.17 73.77
20230109 26.51 74.63
20230110 26.28 75.12
20230111 26.01 77.41
20230112 27.54 78.39
20230113 27.37 79.86
20230117 27.85 80.45
20230118 26.4 79.8
20230119 27.01 80.61
20230120 26.74 81.64
20230123 27.56 81.62
20230124 26.17 80.13
20230125 26.54 80.15
20230126 26.76 81.01
20230127 26.68 79.68
20230130 25.26 77.9
20230131 26.27 78.87
20230201 25.09 76.41
20230202 24.73 75.88
20230203 24.37 73.39
20230206 23.48 74.11
20230207 24.75 77.14
20230208 23.98 78.47
20230209 23.24 78.06
20230210 25.42 79.72
20230213 25.46 80.14
20230214 25.83 79.06
20230215 25.64 78.83
20230216 25.52 78.74
20230217 23.77 76.55
20230221 22.64 76.36
20230222 22.88 73.95
20230223 23.51 75.39
20230224 24.84 76.32
20230227 24.94 75.68
20230228 24.62 77.05
20230301 25.45 77.69
20230302 28.86 78.16
20230303 29.38 79.68
20230306 27.3 80.46
20230307 26.15 77.58
20230308 25.92 76.66
20230309 24.82 75.72
20230310 23.63 76.68
20230313 22.59 74.8
20230314 22.42 71.33
20230315 21.61 67.74
20230316 21.88 68.52
20230317 20.98 66.93
20230320 21 67.82
20230321 21.84 69.67
20230322 20.49 70.9
20230323 20.31 69.96
20230324 20.57 69.26
20230327 22.21 72.81
20230328 22.26 73.2
20230329 22.25 72.97
20230330 22.17 74.37
20230331 22.85 75.67
20230403 24.35 80.42
20230404 23.85 80.71
20230405 24.13 80.61
20230406 23.36 80.7
20230410 23.8 79.74
20230411 25.58 81.53
20230412 25.55 83.26
20230413 25.51 82.16
20230414 25.21 82.52
20230417 24.63 80.83
20230418 24.44 80.9
20230419 24.01 79.24
20230420 23.13 77.37
20230421 23.02 77.87
20230424 24.17 78.76
20230425 22.84 77.07
20230426 22.15 74.3
20230427 22.44 74.76
20230428 23.85 76.78
20230501 23.57 75.66
20230502 21.95 71.66
20230503 21.91 68.6
20230504 21.85 68.56
20230505 22.6 71.34
20230508 22.63 73.16
20230509 23.09 73.71
20230510 22.99 72.56
20230511 22.93 70.87
20230512 23.62 70.04
20230515 24.14 71.09
20230516 23.17 70.84
20230517 24.11 72.89
20230518 24.81 71.94
20230519 24.38 71.69
20230522 25.12 72.05
20230523 25.17 72.91
20230524 25.06 74.34
20230525 23.99 71.83
20230526 23.57 72.67
20230530 23.33 69.46
20230531 23.88 68.09
20230601 24.03 70.1
20230602 25.79 71.74
20230605 25.27 72.15
20230606 26.3 71.74
20230607 27 72.53
20230608 26.93 71.29
20230609 26.74 70.17
20230612 25.85 67.12
20230613 26.63 69.42
20230614 26.11 68.27
20230615 26.73 70.81
20230616 27.13 71.93
20230620 26.65 71.19
20230621 27.09 72.53
20230622 26.42 69.51
20230623 25.45 69.16
20230626 26.55 69.37
20230627 27.1 67.7
20230628 28.51 69.56
20230629 28.95 69.86
20230630 29.12 70.64
20230703 28.95 69.79
20230705 28.33 71.79
20230706 27.27 71.8
20230707 29.06 73.86
20230710 29.71 72.99
20230711 31.05 74.83
20230712 30.86 75.75
20230713 31.04 76.89
20230714 29.29 75.42
20230717 29.65 74.08
20230718 31.3 75.66
20230719 31.05 75.29
20230720 31.31 75.65
20230721 31.82 77.07
20230724 32.58 78.74
20230725 33.54 79.63
20230726 33.71 78.78
20230727 33.63 80.09
20230728 34.83 80.58
20230731 35.81 81.8
20230801 34.74 81.37
20230802 34.06 79.49
20230803 36.66 81.55
20230804 37.01 82.82
20230807 38.91 81.94
20230808 39.64 82.92
20230809 39.94 84.4
20230810 39.44 82.82
20230811 39.36 83.19
20230814 41.53 82.51
20230815 40.47 80.5
20230816 39.91 79.02
20230817 41 79.9
20230818 40.94 80.66
20230821 41.99 80.12
20230822 41.61 79.64
20230823 41.83 78.89
20230824 41.45 79.05
20230825 41.79 79.83
20230828 41.9 80.1
20230829 41.7 81.16
20230830 42.13 81.63
20230831 42.78 83.63
20230901 42.6 85.55
20230905 41.95 86.69
20230906 41.8 87.54
20230907 41.99 86.87
20230908 42.12 87.51
20230911 40.99 87.29
20230912 42.16 88.84
20230913 38.48 88.52
20230914 36.64 90.16
20230915 35.02 90.02
20230918 35.65 90.58
20230919 35.36 90.48
20230920 34.4 89.66
20230921 33.02 89.63
20230922 32.91 90.03
20230925 34 89.68
20230926 34.41 90.39
20230927 35.6 93.68
20230928 36.51 91.71
20230929 35.77 90.79
20231002 33.39 88.82
20231003 33.19 89.23
20231004 31.19 84.22
20231005 30.98 82.31
20231006 32 82.79
20231009 32.98 86.38
20231010 34.15 85.97
20231011 33.17 83.49
20231012 33.46 82.91
20231013 34.6 87.69
20231016 35.54 85.26
20231017 36 85.44
20231018 36.27 87.27
20231019 35.84 88.37
20231020 35.26 88.08
20231023 35.23 85.49
20231024 34.51 83.74
20231025 34.15 85.39
20231026 34.1 83.21
20231027 33.53 85.54
20231030 33.57 82.31
20231031 34.1 81.02
20231101 33.48 80.44
20231102 36.36 82.46
20231103 36.45 80.51
20231106 34.25 80.82
20231107 33.15 77.37
20231108 32.57 75.33
20231109 32.08 75.74
20231110 31.9 77.17
20231113 31.9 78.26
20231114 32.5 78.26
20231115 32.52 76.79
20231116 31.44 73.09
20231117 31.8 76.04
20231120 32.39 77.83
20231121 31.99 77.77
20231122 32.36 77.1
20231124 32.46 75.54
20231127 31.53 74.86
20231128 31.58 76.41
20231129 31.81 77.86
20231130 31.81 75.96
20231201 32.1 74.07
20231204 32.6 73.04
20231205 31.3 72.32
20231206 29.31 69.38
20231207 29.59 69.34
20231208 30.55 71.23
20231211 29.95 71.32
20231212 27.35 68.61
20231213 28.14 69.47
20231214 28.55 71.58
20231215 28.53 71.78
20231218 28.36 72.82
20231219 28.59 73.94
20231220 28.02 74.22
20231221 28.62 73.89
20231222 28.83 73.56
20231226 29.62 75.57
20231227 29.11 74.11
20231228 28.75 71.77
20231229 29.08 71.65
20240102 28.61 70.38
20240103 29.1 72.7
20240104 28.16 72.19
20240105 28.1 73.81
20240108 27.86 70.77
20240109 27.39 72.24
20240110 27.22 71.37
20240111 27.28 72.02
20240112 27.5 72.68
20240116 26.21 72.52
20240117 25.84 72.48
20240118 25.87 73.95
20240119 25.7 73.25
20240122 26.14 74.76
20240123 26.35 74.37
20240124 26.82 75.09
20240125 27.64 77.36
20240126 27.36 78.01
20240129 27.19 76.78
20240130 27.8 77.82
20240131 26.56 75.85
20240201 26.31 73.82
20240202 26.19 72.28
20240205 25.99 72.78
20240206 26.44 73.31
20240207 26.54 73.86
20240208 27.21 76.22
20240209 26.54 76.84
20240212 27.49 76.92
20240213 26.34 77.87
20240214 26.13 76.64
20240215 27.7 77.59
20240216 27.91 78.46
20240220 27.49 77.04
20240221 28.05 77.91
20240222 28.1 78.61
20240223 27.43 76.49
20240226 27.64 77.58
20240227 28.59 78.87
20240228 28.45 78.54
20240229 28.39 78.26
20240301 29.79 79.97
20240304 29.48 78.74
20240305 30.73 78.15
20240306 30.66 79.13
20240307 30.56 78.93
20240308 30.77 78.01
20240311 31.34 77.93
20240312 31.72 77.56
20240313 31.94 79.72
20240314 33.41 81.26
20240315 33.92 80.58
20240318 35.15 82.16
20240319 35.45 82.73
20240320 34.97 81.27
20240321 34.75 81.07
20240322 34.67 80.63
20240325 35.34 81.95
20240326 34.43 81.62
20240327 34.69 81.35
20240328 34.14 83.17
20240401 34.36 83.71
20240402 34.47 85.15
20240403 34.42 85.43
20240404 33.92 86.59
20240405 33.77 86.91
20240408 33.89 86.43
20240409 34.44 85.23
20240410 34.82 86.21
20240411 33.82 85.02
20240412 33.07 85.66
20240415 32.35 84.86
20240416 31.84 84.83
20240417 30.01 82.15
20240418 29.67 82.1
20240419 30.06 82.22
20240422 30.15 81.9
20240423 30.53 83.36
20240424 30.74 82.81
20240425 31.45 83.57
20240426 32.03 83.85
20240429 33.18 82.63
20240430 30.72 81.93
SBOW...O&G prices were lower when SBOW gave guidance in Feburary, so hopefully guidance doesn't drop.
Looks like SBOW just hit what might be a bit of support so I added more in the $29.70's. Makes me heavier in the stock than I want to be, so hopefully I get a chance to sell some off after earnings for higher prices. We'll see what happens,
2024 Outlook:
In response to commodity prices, the Company lowered its previously planned capital investments in dry gas-focused areas by approximately $75 million, resulting in a revised 2024 capital program budget of $470 - $510 million
At current commodity prices, the Company expects to generate $125 - $150 million of estimated FCF, which is currently earmarked for significant debt reduction
The Company is maintaining planned investment in oil and liquids projects while keeping oil and liquids production guidance at previously announced levels. Revised capital investments reduce expected natural gas volumes by 13%
Production is expected to increase approximately 50% year-over-year to 85.2 - 93.5 MBoe/d, post-recent acquisition, oil production is expected to increase 70% year-over-year and comprise 25% - 30% of 2024 production mix
GPN
I have to be honest. I have no idea I listened to the CC. pretty much all the analyst were saying good job with the quarter, which it was.
Here are my theories of why and that is all they are:
1) Payment stocks are down because of the SQ news. Wouldn't concern me in the long run, I'm buying GPN, not SQ.
2) Technical selloff if you look at a chart once it broke the $120 level, It was gonna drop at least in the $110-115 range. There was no support for a while once it broke $120.
3) I could think of is maybe adjusted eps was only like 8% for the quarter, and maybe they were hoping for more, although even that seems crazy considering they beat analyst estimates. They are guiding for 11-12% overall, so maybe they didn't like the eps growth this quarter was less than 11-12%? Albeit Q1 was the strongest y/y quarter by a country mile last year, so the lesser growth y/y might of simply been a much tougher comp with growth on the eps front accelarating in the coming quarters, which I believe will happen, in fact that is what the company is guiding for.
Personally I think reasons #1 and #2 make more sense and neither of which bother me for my view of GPN is significantly undervalued. Time will tell. Although as of right now I was clearly too early with my purchase of GPN. All is just my opinion, and I could always be wrong though.
FISI +.42 to 17.64, thanks for that in depth post. I joined you with a few shares and have some GTC buy orders placed at lower prices ....
SBOW -.73 to 29.99, the culprit behind the recent weakness is falling crude oil prices, now under $80/bbl, down from near $88 just 3 weeks ago ..... NG prices have also been weak due to a supply glut.
GPN down 9% today. What was it about this morning's Q1 report that the market didn't like?
https://finance.yahoo.com/news/global-payments-reports-first-quarter-105500080.html
SBOW...Stock price has hit the sh!tter past couple days, but it hasn't been on overly high volume. So I thought WTH, and added a little more this morning @ avg $30.12. Earnings tomorrow.
AAOI, just bought some @ $9.79
Earnings next week for the March qtr. I'm hopeful that MSFT will have given them more business, as they are increasing their data centers. I think, assuming more MSFT business, that AAOI could post around $1/share going forward. Either way, under $10 is not a bad risk/reward at this point.
GPN
Brought some GPN Today at $114.74. here is what I like.
GPN is a consistent Grower of eps, and that is what I like the most.
FY 24: $11.54-11.70 (Estimate)
FY 23: $10.42
FY 22: $9.32
FY 21: $8.16
FY 20: $6.40
FY 19: $6.22
FY 18: $5.19
FY 17: $4.01
FY 16: $3.19
That is a great track record of EPS growth. Estimates for FY 25 are north of $13. I believe GPN should trade at a 15 multiple. Hence I feel FV should be around $190-$200. But even lets say I'm too optimistic a 12 pe get us to about $160 in about a year. GPN I feel is excellent long-term consistent growth story trading at less than 10 times this years estimates, and less than 9 times next years estimates, for a company that consistentently grows eps by low double digits every year. Time will tell. But I think buying GPN down here will prove to be a very attractive entry point in the long run. Time will tell. Will add more on weakness. All is just my opinion, and I could always be wrong though.
SMCI...Hope you do well valuemind. I had a couple good trading days and am out now.
Still have the urge to trade it though because of the wild swings, so I removed it from my watchlist.
Good luck.👍
PRIM- I sold this morning
Down less than 1% on the trade- just that I think the Infrastructure stocks have already priced in the good times to continue till 2026, from the Infrastructure bill. I mean these stocks(ie TPC, PRIM, and STRL) are up 200% in the last year already !
Tempted to join ya on SMCI. Was in the mid $900's in AH yest. Seems like only a matter of time before it shoots higher again...
Buying back some BURCA in the mid $12's. Boring stock with an excellent 7.3% dividend yield. Seems like an attractive place to park some cash in this wobbly market.
And I thought their Q1 report last week was very solid. Flat earnings. But the year ago Q1 was unusually strong. So quite a feat to match that. I was expecting a sharp decline in Q1 earnings.
https://finance.yahoo.com/news/burnham-holdings-inc-reports-first-153000295.html
Bought back more SMCI at $730
Glad you made some money on the MIND preferreds. Funny I skimmed the CC transcript this morning. They actually said they wouldn't be answering any questions on the call about the preferred situation. Think I also heard that $5M in revenue was delayed from Q3 into Q4. Backlog still very strong, but sounds like some lumpy quarters coming up. I'm staying away with the preferred mess. But she's got a low float so who knows.
2morrowsGains: I bought back some SMCI at $742 because the third fiscal quarter ending March 31 is usually seasonally weak for SMCI, yet its revenue sequentially rose 5% and it is strength for me. Of course many investors misunderstood 5% sequential rise in revenue as a weakness from competition.
MIND / MINDP - I've been in and out of the preferred recently. It's a really interesting situation with the company trying to get the preferred holders to convert into common. The company seems pretty emphatic about wanting to preserve its working capital and thus doesn't want to pay out the preferred dividend at this time.
The preferred holders were supposed to vote on it on April 25, but the company postponed it to a yet undetermined date. Maybe they knew they didn't have the votes or maybe they wanted to get that good earnings report out ahead of it.
Good times coming to an end by May 31 IMO
AI is the only reason this market has held up so well, and after SMCI last night, I think the party is winding down. I have for a long time said this whole market since Oct 2022, has been a bear market rally, and I still think that. I would say, there will soon be little place to hide. I mean it's been the AI stocks, selected tech, energy, Infrastructure, and metals, but I think it's time to abandon those sectors as well. If I had one sector to pick to be in, it would be selected healhcare. I think the market gets much tougher from here for the rest of the year.
SBUX seemed to have a solid miss...
https://stocktwits.com/wallstengine/message/571333945
Question isn't the economy...
How does a coffee selling company
miss in a winter quarter?...
Too many working and not enough to
sit and drink coffee?...
So we watch...LJ
So the market tanks and oil price drops,
so why is U.S. Dollar up?...
On the Ai chips, the company with
the contracts to get chips to go into
products are in the lead,,,
Company already in that loop, should
have some advantage on the hard
side too...perhaps...
ARM is really the company in the cat
bird seat as long as Ai keeps rocking,
but seems priced in at its high price...
NVDA leadership is tied to TSM contracts
and their OpenAi connection...
Need to find a decent oil play during
this flop period...
So we watch...LJ
SMCI has a market cap of $50B, HPE is a mere $22B while DELL is $88B ....
HPE, Hewlett Packard Enterprises, has a forward PE of only around 9, so if they snatch some market share from SMCI and become viewed as an AI server growth story, the stock could see a lot of multiple expansion.
AMZN beat got whupped like SMCI
beat in after hours...
https://stocktwits.com/NewsByNick/message/571329500
What happens in afterhours stays
in after hours...
SMCI only has smidgen of sector sales
in comps to DELL and HPQ...
It is the much lower share count of SMCI
with a high price tag that shocks folks...
Oil price being brought down on Tuesday
and maybe Wednesday should give out
company price deals along the way...
The over priced oil for most of 2024,,,
now goes into period when higher prices
should start looking more correct,,,Opec
producers use a lot more of their own
production to cool in summer and it has
already started warming up there,,,And a
lower supply for world markets will occur
unless Opec+ increases oil production...
Just between us...
So we watch...LJ
SMCI - as I posted a few weeks ago, the AI server business has lower barriers to entry than the AI chip design business - SMCI will be experiencing increasing margin pressure in the coming months. The stock could be a good short term trader, but not a long term hold, imho.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173852229&txt2find=dell
DELL, HP
SMCI, if every company reported .87/share higher
than expected, the whole market
might implode...
NVDA was a small snag in after hours...
SMCI was a small snag at 4 times more
than NVDA in after hours...
This whole stupid day may have been a
set up for the wheels to kiss the ring of
J.P. with a rally coming next...
SMCI stunned me with the good numbers...
Peons are often easily impressed though...
ERX put calls for 70 were closed today
to not leave any profit on table...Oilies could
bounce with everything else...
So we watch...LJ
SMCI revenues were "hurt from stiff competition"
That's the entire reason the stock is getting hit. I mean it's nice that they are giving strong guidance, but they came in with lower revenues for the March qtr than guided for, and investors are concerned they could do that again in the June qtr. Bottom line is, they no longer have monopoly status. I wouldn't touch the stock based on that, despite the strong June qtr guidance. I think the stock is worth around $700-$750 and that's all the money. So to be a good buy, it has to go down to $650 or so IMO. Here is a link...
https://finance.yahoo.com/news/super-micro-forecasts-quarterly-revenue-200957932.html
SMCI($730)- down $130 after hours !
SMCI($758) now down $100 after hours ?
This despite giving such strong guidance of around $8 for the June qtr ?
SSKMP Managed Index (As Of 4/30/24)
Daily Performance
-0.27%
YTD Performance
+0.91%
Overall Performance
+476.18% (Including Options Trading +340.16%)
SMCI after hours range is now 797 to 947 .... with the stock currently at 858. Crazy action over just a few minutes! Who knows where it settles ???
Followers
|
405
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
113894
|
Created
|
02/09/13
|
Type
|
Free
|
Moderator SSKILLZ1 | |||
Assistants hweb2 abh3vt wadegarret researcher59 Knowledge is King nelson1234 |
Posts Today
|
2
|
Posts (Total)
|
113894
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |